On the November 12th, the international index compilation company MSCI announced the results of the November quarterly index review. Shanghai Medicilon Inc. (stock code: 688202.SH) has been added to the MSCI China A-Share Index by virtue of its stable performance on the Sci-tech Innovation Board since its listing. This will take effect after the market closes on November 30, 2021.
The selection of Medicilon fully demonstrates the recognition and optimism of the capital market for the company’s performance growth, the competitive advantage of scientific research services, and the market position. According to the third quarter report released by Medicilon, the company’s income in the first three quarters of 2021 reached RMB 786 million, an increase of 81.62% over the same period of the previous year.
As a professional preclinical R&D service CRO, Medicilon has continued to innovate and grow in the course of 17 years of development, and continue to accumulate clients around the world, and provide them with efficient and cost-effective R&D services. Currently, Medicilon has a R&D laboratory of 73,800 square meters, more than 2,000 employees, and more than 1,100 clients worldwide, and has successfully assisted 165 R&D projects to be registered.
Congratulations to Medicilon for being selected in MSCI China Index, and wish Medicilon to make persistent efforts and move forward courageously!